Pharmaceutical Industry

The real beneficiaries of high sugar consumption are pharmaceutical companies and the junk food industry, not the consumer. Major pharmaceutical companies have collectively accumulated over $126 billion in penalties since 2000. Pfizer accumulated approximately $11 billion in penalties across 107 violations. Public trust in pharmaceutical corporations has been declining, and television advertising reaches an increasingly skeptical audience. Pharmaceutical dependence is the primary downstream outcome of sustained high sugar intake, and the system is structured to profit from it rather than prevent it. Because corporations cannot purchase trust directly, they rent it from influencers who have already built it organically with their audiences. Over $60 billion of pharmaceutical penalties are specifically related to patient injury and harm, not regulatory technicalities. Sustained sugar consumption makes individuals long-term customers of drug companies.